Ghent University Academic Bibliography

Journal Article
A1
open access

Safety and immunogenicity of an adjuvanted clostridioides difficile vaccine candidate in healthy adults : a randomized placebo-controlled phase 1 study

Isabel Leroux-Roels (UGent) , Azhar Alhatemi (UGent) , Magalie Caubet, Fien De Boever (UGent) , Bertrand de Wergifosse, Mohamed El Idrissi, Guilherme S Ferreira, Bart Jacobs (UGent) , Axel Lambert, Sandra Morel, et al.

(2025) JOURNAL OF INFECTIOUS DISEASES. 231(3). p.e511-e520

Add to list

Journal Article
A1
open access

A novel carbohydrate fatty-acid monosulphate ester, squalane-in-water adjuvant is safe and enhances inactivated influenza vaccine immunogenicity in older adults

Valentino D'Onofrio (UGent) , Bart Jacobs (UGent) , Azhar Alhatemi (UGent) , Simon De Gussem (UGent) , Marjolein Verstraete (UGent) , Sharon Porrez (UGent) , Anthony Willems (UGent) , Fien De Boever (UGent) , Gwenn Waerlop (UGent) , Geert Leroux-Roels (UGent) , et al.

(2025) VACCINES. 13(9).

Add to list

Journal Article
A1
open access

Evaluation of safety, immunogenicity and cross-reactive immunity of OVX836, a nucleoprotein-based universal influenza vaccine, in older adults

Bart Jacobs, Isabel Leroux-Roels (UGent) , Jacques Bruhwyler, Nicola Groth, Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Jessika Tourneur, Fien De Boever (UGent) , Azhar Alhatemi (UGent) , Philippe Moris, et al.

(2024) VACCINES. 12(12).

Add to list

Journal Article
A1
open access

Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Valentino D'Onofrio (UGent) , Sharon Porrez (UGent) , Bart Jacobs (UGent) , Azhar Alhatemi (UGent) , Fien De Boever (UGent) , Gwenn Waerlop (UGent) , Els Michels, Francesca Vanni, Alessandro Manenti, Geert Leroux-Roels (UGent) , et al.

(2024) VACCINES. 12(9).

Add to list

Journal Article
A1
open access

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults : a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Isabel Leroux-Roels (UGent) , Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F Rimmelzwaan, Albert D M E Osterhaus, Simone Kardinahl, Sabrina Pelz, Stephan Bauer, Valentino D'Onofrio (UGent) , et al.

(2024) LANCET INFECTIOUS DISEASES. 24(11). p.1245-1253

Add to list

Journal Article
A1
open access

Safety and immunogenicity of a 4-component generalized modules for membrane antigens Shigella vaccine in healthy European adults : randomized, phase 1/2 study

Isabel Leroux-Roels (UGent) , Cathy Maes, Francesca Mancini, Bart Jacobs (UGent) , Eleanna Sarakinou, Azhar Alhatemi (UGent) , Jasper Joye, Silvia Grappi, Giulia Luna Cilio, Alimamy Serry-Bangura, et al.

(2024) JOURNAL OF INFECTIOUS DISEASES. 230(4). p.e971-e984

Add to list

Conference Paper
C3
open access

Changes in myocardial operational stiffness in mechanically ventilated sheep can be detected by measuring natural shear wave propagation speed

Bart Jacobs, Annette Caenen (UGent) , Stephanie Bezy, Laurine Wouters, P. Claus, Bart Meyns, Lies Langouche and Jan Dhooge

(2023) INTENSIVE CARE MEDICINE EXPERIMENTAL. In Intensive Care Medicine Experimental 11(Supplement 1). p.102-103

Add to list

Journal Article
A1
open access

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Bart Jacobs (UGent) , Franziska Jarczowski, André Diessner, Geert Leroux-Roels (UGent) , Victor Klimyuk, Isabel Leroux-Roels (UGent) and Frank Thieme

(2023) FRONTIERS IN IMMUNOLOGY. 14.

Add to list

Journal Article
A1
open access

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

Isabel Leroux-Roels (UGent) , Paul Willems, Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Jessika Tourneur, Fien De Boever (UGent) , Jacques Bruhwyler, Azhar Alhatemi (UGent) , Bart Jacobs (UGent) , Florence Nicolas, et al.

(2023) LANCET INFECTIOUS DISEASES. 23(12). p.1360-1369

Add to list

Journal Article
A1
open access

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Isabel Leroux-Roels (UGent) , Cathy Maes, Jasper Joye, Bart Jacobs (UGent) , Franziska Jarczowski, André Diessner, Yorick Janssens (UGent) , Gwenn Waerlop (UGent) , Kirsi Tamminen, Suvi Heinimäki, et al.

(2022) FRONTIERS IN IMMUNOLOGY. 13.

Academic Bibliography

Safety and immunogenicity of an adjuvanted clostridioides difficile vaccine candidate in healthy adults : a randomized placebo-controlled phase 1 study

A novel carbohydrate fatty-acid monosulphate ester, squalane-in-water adjuvant is safe and enhances inactivated influenza vaccine immunogenicity in older adults

Evaluation of safety, immunogenicity and cross-reactive immunity of OVX836, a nucleoprotein-based universal influenza vaccine, in older adults

Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults : a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Safety and immunogenicity of a 4-component generalized modules for membrane antigens Shigella vaccine in healthy European adults : randomized, phase 1/2 study

Changes in myocardial operational stiffness in mechanically ventilated sheep can be detected by measuring natural shear wave propagation speed

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Contents

Support

Contact